nach oben

Current Bladder Dysfunction Reports

Erschienen in:

01.03.2014 | Overactive Bladder (U Lee, Section Editor)

Economics of Overactive Bladder

verfasst von: Melissa Sanford, Donna Y. Deng

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

OAB is a prevalent, costly disease that has significant personal and societal burdens. Therapy should graduate in invasiveness as necessary. Behavioral modification techniques are the ideal starting point. Anticholinergic medications should be used as the initial medical management. Drug selection should take into consideration individual patient needs regarding side-effect profile. Patients who fail to improve on medication alone should be offered 2nd line therapies including neuromodulation (SNS or PTNS) or intravesical injection of botulinum toxin A. Surgical options such as augmentation cystoplasty and diversion should be reserved for patients with neurogenic OAB who have failed other more conservative measures.

Abrams P, Cardozo L, Fall M, et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.PubMedCrossRef

Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14.PubMedCrossRef

Stewart WF, Van Rooven JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.PubMed

Milsom I. Lower urinary tract symptoms in women. Curr Opin Urol. 2009;19(4):337–41. doi:10.1097/MOU.0b013e32832b659d. Review.PubMedCrossRef

Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96–100.PubMedCrossRef

Cohen BL, Barboglio P, Gousse A. The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument. J Sex Med. 2008;5(6):1418–23.PubMedCrossRef

Cisternas MG, Foreman AJ, Marshall TS, Runken MC, Kobashi KC, Seifeldin R. Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage. Curr Med Res Opin. 2009;25(4):911–9.PubMedCrossRef

Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy. 2005;25(4):511–9.PubMedCrossRef

Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–S107.PubMed

10.

Wu EQ, Birnbaum H, Marynchenko M, et al. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005;47(5):439–46.PubMedCrossRef

11.

Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32. 532.e1-18.PubMedCrossRef

12.

Ricci JA, Baggish JS, Hunt TL, et al. Coping strategies and health-care seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther. 2001;23(8):1245–59.PubMedCrossRef

13.

Thuroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Actas Urol Esp. 2001;35(7):373–88.

14.

Nabi G, Cody JD, Ellis G, et al. Anticholingeric drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;4, CD003781.PubMed

15.

• Rai BP, Cody JD, Alhasso A, et al. Anticholingeric drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12, CD003193. Cochrane review examining 23 trials of idiopathic OAB found there was a significant symptomatic improvement when anticholinergic treatment was added to bladder training (RR 0.57, CI 0.38-0.88) compared to bladder training alone (RR 0.74, CI 0.61-0.91), but it is unclear if anticholinergic therapy combined with bladder training is superior to anticholinergic therapy alone (RR 0.80, CI 0.62-1.04).PubMed

16.

Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.PubMedCrossRef

17.

Cardozo L, Thorpe A, Warner J, et al. The cost-effectiveness of solifenacin vs. fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. BJU Int. 2010;106(4):506–14.PubMedCrossRef

18.

• Armstrong EP, Malone DC, Bui CN. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder. J Med Econ. 2012;15 Suppl 1:35–44. doi:10.3111/13696998.2012.732635. Compared the treatment effect and cost of darifenacin, fesoterodine, oxybutynin IR, oxybutynin ER, oxybutynin topical gel, oxybutynin patch, solifenacin, tolterodine IR, tolterodine ER, trospium IR, and trospium ER. Oxybutynin IR was the most cost-effective low cost option and solifenacin was the most cost-effective higher cost option.PubMedCrossRef

19.

• Staskin DR, Peters KM, MacDiarmid S. Percutaneous tibial nerve stimulation; a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep. 2012;12:327–34. Recommend consideration of PTNS prior to implantation of SNS given its less invasive nature, fewer adverse effects, and lower cost compared to SNS.CrossRef

20.

Imran M, Najmi AK, Tabrez S. Mirabegron for overactive bladder: a novel first-in-class β3-agonist therapy. Urol J. 2013;10(3):935–40.PubMed

21.

Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Autralian Phase 3 trial. BMC Urol. 2013;13(1):45.PubMedCentralPubMedCrossRef

22.

Chapple C, De Ridder D. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice? BJU Int. 2009;104:1188–90.PubMedCrossRef

23.

Burton C, Sajja A, Latthew PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16.PubMedCrossRef

24.

Chen HW, Bercik RS, Werner EF, Thung SF. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. J Urol. 2012;187(1):178–84.PubMedCrossRef

25.

Cameron AP, Anger JT, Madison R. National trends in the usage and success of sacral nerve test stimulation. J Urol. 2011;185(3):970–5.PubMedCentralPubMedCrossRef

26.

Anger JT, Cameron AP, Madison R. The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population. Neuromodulation. 2013 May 3.

27.

Al-Zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol. 2011;185:981–6.PubMedCrossRef

28.

Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189(1):210–6. doi:10.1016/j.juro.2012.08.085.PubMedCrossRef

29.

Karsenty G, Denys P, Amarenco G. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53(2):275–87.PubMedCrossRef

30.

Gomez CS, Kanagarajah P, Gousse A. The use of botulinum toxin a in idiopathic overactive bladder syndrome. Curr Urol Rep. 2010;11(5):353–9.PubMedCrossRef

31.

Novara G. Botulinum neurotoxin type A: the poison that can treat the sick. Eur Urol. 2009;55:560–2.PubMedCrossRef

32.

Giannantoni A, Mearini E, Del Zingaro M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol. 2009;55:705–12.PubMedCrossRef

33.

Chancellor MD. Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observation and research discovery. Int Urol Nephrol. 2010;42(2):383–91.PubMedCrossRef

34.

Wefer B, Ehlken B, Bremer J. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol. 2010;28(3):385–90.PubMedCrossRef

35.

Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010;76(4):835–40.PubMedCrossRef

36.

Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int. 2011;108(4):558–64.PubMedCrossRef

37.

• Arlandis S, Castro D, Errando C, Fernández E, Jiménez M, González P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Value Health. 2011;14(2):219–28. Used Markov modeling to examine cost effectiveness of SNS vs. BoNTA vs. medial therapy and found SNS to be the most effective option at 10 years due to its reduced follow-up costs and consistently greater effectiveness, despite having the most expensive upfront costs.PubMedCrossRef

38.

Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol. 2011;29(1):51–7.PubMedCrossRef

Titel: Economics of Overactive Bladder
verfasst von: Melissa Sanford
Donna Y. Deng
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 1/2014
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-013-0220-9

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Consideration in Quality and Safety for Pelvic Floor Interventions

History of the Term “Overactive Bladder”

The Effectiveness of Bladder Training in Overactive Bladder

Current Assessment and Management of Fecal Incontinence